GlassScriptPhysician profile
Kathryn Wayne Anzueto
NPI 1821697285
$3,107.00
in general payments reported to CMS, 2019-2025
19 companies · $871 in 2025
The $871 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $520 · 2023: $836 · 2024: $570 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $368.47 | 2023-2025 | Darzalex, Tecvayli, Erleada |
| E.R. Squibb & Sons, L.L.C. | $343.09 | 2022-2023 | Reblozyl |
| Genzyme Corporation | $259.00 | 2022-2024 | |
| Abbvie INC. | $249.96 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $246.79 | 2023-2025 | |
| Incyte Corporation | $239.42 | 2023-2025 | Niktimvo, Jakafi |
| Amgen INC. | $232.42 | 2021-2025 | Blincyto |
| Celgene Corporation | $229.26 | 2021-2025 | Breyanzi |
| Seagen INC. | $121.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $119.03 | 2023 | Imfinzi |
| Legend Biotech USA INC. | $118.00 | 2023-2024 | Carvykti |
| Pharmacosmos Therapeutics INC. | $110.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $100.94 | 2022 | |
| Kite Pharma, INC. | $100.33 | 2023-2024 | Yescarta |
| Eisai INC. | $96.88 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.58 | 2025 | |
| Alcresta Therapeutics, INC. | $39.47 | 2023 | Relizorb |
| Astellas Pharma US INC | $33.30 | 2025 | Cresemba |
| Stemline Therapeutics INC. | $24.67 | 2024 | Elzonris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Anzueto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.